Choline
Evidence Fact Sheet
Choline is an essential nutrient and precursor for acetylcholine and phosphatidylcholine, also feeding one-carbon (betaine/homocysteine) metabolism and hepatic lipid export. US Adequate Intake ~425-550 mg/day; UL 3500 mg/day. EFSA authorizes lipid, liver, and homocysteine claims; cognitive claims were not authorized.
Also known as: Choline · Colina · Choline bitartrate · Choline chloride · Vitamin B4 (former designation)
Overview
Choline is a recognized essential nutrient (IOM 1998) and a precursor for the neurotransmitter acetylcholine and for phosphatidylcholine, a structural membrane phospholipid synthesized via the Kennedy pathway. Through oxidation to betaine it also serves as a methyl-group donor in the methionine-homocysteine remethylation cycle, and it is required for VLDL assembly and hepatic lipid export. Research and supplement forms include choline bitartrate and choline chloride, with US Adequate Intake of 550 mg/day (men) and 425 mg/day (women) and a Tolerable Upper Intake Level of 3500 mg/day for adults; CDP-choline and alpha-GPC are distinct delivery forms studied separately. Regulatory status: lawful GRAS food/supplement ingredient in the US with a 550 mg Daily Value, three EFSA-authorized Reg 432/2012 claims (normal lipid metabolism, normal liver function, normal homocysteine metabolism), and recognized as a nutritional fortifier in China and an ANVISA-listed nutrient in Brazil. EFSA did not authorize cognitive or neurological claims.
Mechanism of Action
Precursor for acetylcholine synthesis (cholinergic neurotransmission) · Substrate for phosphatidylcholine and sphingomyelin synthesis — cell-membrane structural integrity (Kennedy pathway) · Methyl-group donor via oxidation to betaine, feeding the methionine-homocysteine remethylation cycle (BHMT pathway, synergistic with folate/B12) · Required for VLDL assembly and hepatic lipid export (deficiency drives hepatic steatosis)
Body systems: BRAIN · Liver & Detoxification · Reproductive · METABOLISM · Cellular Renewal
Evidence-Based Benefits
Each benefit below is anchored to a specific PubMed-indexed study. Effect sizes, sample sizes, and p-values are reported as published; no values are inferred. Honest negatives and null results are kept alongside the positive findings, and disease-research populations are described as such — Choline is not characterized as a treatment for any disease.
Liver Function / Choline Deficiency
RCT supported- 77% mendeveloped fatty liver/muscle damage
- 80%postmenopausal women
- 44%premenopausal women
In a controlled human depletion study, removing dietary choline produced fatty liver or muscle damage in most men and postmenopausal women but fewer than half of premenopausal women, demonstrating that adequate choline is required for normal liver function and that susceptibility varies by sex and menopausal status. This supports the research-context direction behind the EFSA-authorized normal-liver-function claim.
Reported effect: 77% of men and 80% of postmenopausal women developed fatty liver or muscle damage on the choline-deprived diet vs only 44% of premenopausal women
“When deprived of dietary choline, 77% of men and 80% of postmenopausal women developed fatty liver or muscle damage, whereas only 44% of premenopausal women developed such signs of organ dysfunction.”
Source: PMID 17490963 · Fischer 2007 · Am J Clin Nutr
Maternal Choline & Infant Cognition (Single RCT)
RCT supported- P = 0.03reaction time · 930 vs 480 mg/d
- n = 26pregnant participants
In a controlled feeding RCT during the third trimester, infants born to mothers assigned 930 mg/day choline had significantly faster mean reaction time (an information-processing-speed measure) across four ages than infants in the 480 mg/day group. This is a small single trial; framed as a research finding, not a treatment claim.
Reported effect: Mean infant reaction time averaged across four ages significantly faster for the 930 vs 480 mg choline/d group (P = 0.03); n = 26 pregnant participants
“Mean reaction time averaged across the four ages was significantly faster for infants born to mothers in the 930 ( vs. 480) mg choline/d group.”
Source: PMID 29217669 · Caudill 2018 · FASEB J
Choline in Pregnancy & Child Neurodevelopment (Pooled — Honest Negative)
Null / no benefit Meta-analysis supported- 4 RCTs+ 5 observational pooled
- 20 publicationsneurodevelopment outcomes
A systematic review pooling 4 randomized trials and 5 observational studies concluded current evidence is insufficient to support or refute that higher prenatal choline improves child neurodevelopment, with most assessed outcomes null. This is an honest negative that tempers the single positive RCT above and is consistent with EFSA not authorizing cognitive claims.
Reported effect: Across 4 RCTs and 5 observational studies (20 publications), most neurodevelopmental outcomes did not support benefit; evidence judged insufficient
“Current evidence is insufficient to support or refute the hypothesis that increasing choline intake in pregnancy improves the neurodevelopmental outcomes of the child.”
Source: PMID 40077755 · Gould 2025 · Nutrients
Homocysteine Metabolism (Betaine Pathway)
Meta-analysis supported- -1.23 μmol/Lplasma homocysteine · P=.01
- 5 RCTsbetaine 4-6 g/day
Choline is oxidized to betaine, the methyl donor in the betaine-homocysteine methyltransferase (BHMT) remethylation pathway. A meta-analysis of 5 RCTs of betaine supplementation found a statistically significant reduction in plasma homocysteine, mechanistic support for the EFSA-authorized normal-homocysteine-metabolism direction. Note the trials dosed betaine, choline's downstream metabolite, not choline itself.
Reported effect: Pooled reduction in plasma homocysteine of 1.23 μmol/L (95% CI -1.61 to -0.85; P = .01) across 5 RCTs of betaine 4-6 g/day
“The pooled estimate of effect for betaine supplementation on plasma homocysteine was a reduction of 1.23 μmol/L, which was statistically significant (95% confidence interval, - 1.61 to - 0.85; P = .01).”
Source: PMID 23997720 · McRae 2013 · J Chiropr Med
Dietary Choline & Incident Cardiovascular Disease (Honest Negative)
Null / no benefit Meta-analysis supported- RR 1.00incident CVD · 95% CI 0.98-1.02
- 184,010participants · 6 studies
A meta-analysis of six prospective cohorts (184,010 participants, 18,076 CVD events) found no association between dietary choline intake and incident cardiovascular disease. A null finding that argues against a direct dietary choline-CVD link at usual intakes.
Reported effect: Incident CVD not associated with choline intake (RR 1.00; 95% CI 0.98, 1.02); 6 studies, 184,010 participants, 18,076 CVD events
“In random-effects meta-analysis, incident CVD was not associated with choline (relative risk (RR): 1.00; 95% CI: 0.98, 1.02) intake.”
Source: PMID 28686188 · Meyer 2017 · Nutrients
Higher Dietary Choline Intake & Mortality (Cohort Signal)
Null / no benefit Meta-analysis supported- RR 1.06all-cause mortality · per 100 mg/d
- RR 1.11CVD mortality · per 100 mg/d
A dose-response meta-analysis of six cohorts (482,778 participants) found each 100 mg/day higher choline intake associated with modestly higher all-cause and cardiovascular mortality. Observational association (not causation) flagged as a counterweight to high-intake framing and consistent with the card's TMAO safety note.
Reported effect: Each 100 mg/day higher choline intake associated with all-cause mortality RR 1.06 (95% CI 1.03, 1.10) and CVD mortality RR 1.11 (95% CI 1.06, 1.16); 6 cohorts, 482,778 participants
“each 100 mg/day increase in choline intake was significantly associated with 6% and 11% increases in risk of all-cause (RR = 1.06, 95% CI: 1.03, 1.10) and cardiovascular diseases mortality (RR = 1.11, 95% CI: 1.06, 1.16), respectively.”
Source: PMID 39341000 · Sharifi-Zahabi 2024 · Nutr Res
Dosage (research context · not a recommendation)
Educational reference, not a dosing recommendation. US Adequate Intake (AI): 550 mg/day men, 425 mg/day women; pregnancy 450 mg/day, lactation 550 mg/day; FDA Daily Value 550 mg. Tolerable Upper Intake Level (UL) 3500 mg/day (adults). Research/supplement forms: choline bitartrate, choline chloride; CDP-choline 500-2000 mg/day and alpha-GPC 600-1200 mg/day are distinct delivery forms studied separately.
Regulatory Status · 4 Markets
- US · FDA
- Recognized essential nutrient (IOM 1998); FDA Daily Value 550 mg (2016). Multiple forms (choline bitartrate, choline chloride, alpha-GPC, CDP-choline) are lawful GRAS dietary-supplement / food ingredients; structure/function claims with mandatory DSHEA disclaimer; no FDA-authorized health claim.
- EU · EFSA
- Three authorized Reg 432/2012 Art.13.1 health claims: choline contributes to normal lipid metabolism, to maintenance of normal liver function, and to normal homocysteine metabolism (EFSA Journal 2011;9(9):2056). Cognitive/neurological claims were NOT authorized.
- CN · China
- Choline (bitartrate/chloride) is a lawful GB 14880 nutritional fortifier; mandatory in infant formula; usable in health foods.
- BR · ANVISA
- ANVISA-recognized nutrient usable in food supplements (RDC 269/2005 referencing international references; IN 28/2018 supplement framework). Listed nutrient ingredient; no specific Anexo V functional claim distinct from nutrient declaration.
Authorized Claims
EFSA — “Choline contributes to normal lipid metabolism” (Reg 432/2012)
EFSA — “Choline contributes to the maintenance of normal liver function” (Reg 432/2012)
EFSA — “Choline contributes to normal homocysteine metabolism” (Reg 432/2012)
Safety
Generally well tolerated within the AI/UL range. High intake (>3500 mg/day) can cause fishy body odor (trimethylamine accumulation), sweating, hypersalivation and hypotension. Trimethylaminuria (TMAU / fish-odor syndrome) patients must restrict choline. Gut microbiota convert choline to TMA, hepatically oxidized to TMAO; high TMAO has been epidemiologically associated with cardiovascular risk (causality unestablished) — balance high-dose framing. A 2021 retrospective cohort suggested long-term alpha-GPC use mildly associated with stroke risk (form-specific signal, monitor). No adequate data beyond established nutrient-reference contexts; not medical advice.
Related
Goals: cognitive-support · heart-health
Lifestyles: pregnancy · senior-60-plus
References
PubMed-indexed citations anchoring the benefit findings above. Effect sizes are reported as published.
- PMID 17490963 · Fischer 2007 · Am J Clin Nutr — Liver Function / Choline Deficiency
- PMID 29217669 · Caudill 2018 · FASEB J — Maternal Choline & Infant Cognition (Single RCT)
- PMID 40077755 · Gould 2025 · Nutrients — Choline in Pregnancy & Child Neurodevelopment (Pooled — Honest Negative)
- PMID 23997720 · McRae 2013 · J Chiropr Med — Homocysteine Metabolism (Betaine Pathway)
- PMID 28686188 · Meyer 2017 · Nutrients — Dietary Choline & Incident Cardiovascular Disease (Honest Negative)
- PMID 39341000 · Sharifi-Zahabi 2024 · Nutr Res — Higher Dietary Choline Intake & Mortality (Cohort Signal)
Frequently Asked Questions
1. Is choline good for the brain and cognition?
The evidence is mixed and not settled. One controlled-feeding RCT (Caudill 2018) found infants of mothers given 930 vs 480 mg/day choline had faster reaction times (P=0.03), but a later systematic review pooling 4 RCTs and 5 observational studies (Gould 2025) concluded the evidence is insufficient to support or refute that higher prenatal choline improves child neurodevelopment, with most outcomes null. EFSA did not authorize any cognitive or neurological claim for choline. This is an evidence summary, not health advice.
2. Why is choline linked to liver function?
Choline is required for VLDL assembly and hepatic lipid export. In a controlled human depletion study (Fischer 2007), removing dietary choline led to fatty liver or muscle damage in 77% of men and 80% of postmenopausal women, versus 44% of premenopausal women, showing susceptibility differs by sex and menopausal status. This underlies the EFSA-authorized 'normal liver function' claim direction.
3. Does choline lower homocysteine?
Choline is oxidized to betaine, the methyl donor in the BHMT remethylation pathway. A meta-analysis of 5 RCTs (McRae 2013) found betaine supplementation reduced plasma homocysteine by 1.23 μmol/L (95% CI -1.61 to -0.85; P=.01). Note those trials dosed betaine, choline's downstream metabolite, rather than choline itself. EFSA authorizes a 'normal homocysteine metabolism' claim for choline.
4. Is more choline always better for heart health?
Not necessarily. A meta-analysis of 6 cohorts (Meyer 2017) found dietary choline intake was not associated with incident cardiovascular disease (RR 1.00; 95% CI 0.98-1.02), while a separate dose-response meta-analysis (Sharifi-Zahabi 2024) found each 100 mg/day higher intake associated with modestly higher all-cause (RR 1.06) and cardiovascular (RR 1.11) mortality. These are observational associations, not proof of causation, and align with the card's note that gut-derived TMAO from high choline has been epidemiologically tied to cardiovascular risk.
Last evidence review: 2026-06-22